Chemo-radiotherapy in non-small cell lung cancer: The role of gemcitabine

L. Trodella; R. M. D'Angelillo; S. Ramella; F. Cellini; Francesco Cellini; M. Ciresa; Alfredo Cesario; Pierluigi Granone

doi:10.1093/annonc/mdj950

Chemo-radiotherapy in non-small cell lung cancer: The role of gemcitabine

L. Trodella
, R. M. D'Angelillo
, S. Ramella
, F. Cellini
, Francesco Cellini
, M. Ciresa
, Alfredo Cesario
, Pierluigi Granone

Universita Campus Bio-Medico di Roma

Risultato della ricerca: Contributo in rivista › Articolo

Abstract

Gemcitabine (2′-2′-difluorodeoxycytidine) is a well-known cytotoxic drug and a potent radio-enhancer. We herein report the in vitro evidence of its activity, and the clinical experiences when this drug is administered concurrently with radiation. The phase I-II trials are analyzed, focusing on the recent ability to deliver irradiation with low incidence of side effects. © 2006 Oxford University Press.

Lingua originale	Inglese
pagine (da-a)	v52-v54
Rivista	Annals of Oncology
Volume	17
DOI	https://doi.org/10.1093/annonc/mdj950
Stato di pubblicazione	Pubblicato - 2006

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Keywords

n/a

Accesso al documento

10.1093/annonc/mdj950

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{246d4520faac441a8229f75f70eafdb0,

title = "Chemo-radiotherapy in non-small cell lung cancer: The role of gemcitabine",

abstract = "Gemcitabine (2′-2′-difluorodeoxycytidine) is a well-known cytotoxic drug and a potent radio-enhancer. We herein report the in vitro evidence of its activity, and the clinical experiences when this drug is administered concurrently with radiation. The phase I-II trials are analyzed, focusing on the recent ability to deliver irradiation with low incidence of side effects. {\textcopyright} 2006 Oxford University Press.",

keywords = "n/a, n/a",

author = "L. Trodella and D'Angelillo, \{R. M.\} and S. Ramella and F. Cellini and Francesco Cellini and M. Ciresa and Alfredo Cesario and Pierluigi Granone",

year = "2006",

doi = "10.1093/annonc/mdj950",

language = "English",

volume = "17",

pages = "v52--v54",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Chemo-radiotherapy in non-small cell lung cancer: The role of gemcitabine

AU - Trodella, L.

AU - D'Angelillo, R. M.

AU - Ramella, S.

AU - Cellini, F.

AU - Cellini, Francesco

AU - Ciresa, M.

AU - Cesario, Alfredo

AU - Granone, Pierluigi

PY - 2006

Y1 - 2006

N2 - Gemcitabine (2′-2′-difluorodeoxycytidine) is a well-known cytotoxic drug and a potent radio-enhancer. We herein report the in vitro evidence of its activity, and the clinical experiences when this drug is administered concurrently with radiation. The phase I-II trials are analyzed, focusing on the recent ability to deliver irradiation with low incidence of side effects. © 2006 Oxford University Press.

AB - Gemcitabine (2′-2′-difluorodeoxycytidine) is a well-known cytotoxic drug and a potent radio-enhancer. We herein report the in vitro evidence of its activity, and the clinical experiences when this drug is administered concurrently with radiation. The phase I-II trials are analyzed, focusing on the recent ability to deliver irradiation with low incidence of side effects. © 2006 Oxford University Press.

KW - n/a

UR - http://hdl.handle.net/10807/204839

U2 - 10.1093/annonc/mdj950

DO - 10.1093/annonc/mdj950

M3 - Article

SN - 0923-7534

VL - 17

SP - v52-v54

JO - Annals of Oncology

JF - Annals of Oncology

ER -

Chemo-radiotherapy in non-small cell lung cancer: The role of gemcitabine

Abstract

OSS delle Nazioni Unite

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo